Abstract：
UNASSIGNED: We aimed to evaluate the efficacy and safety of granulocyte-colony stimulating factor (G-CSF) prophylaxis during chemoimmunotherapy with carboplatin plus etoposide and atezolizumab in extensive-stage small cell lung cancer (ES-SCLC).
UNASSIGNED: This retrospective, multicenter study enrolled ES-SCLC patients receiving carboplatin plus etoposide and atezolizumab, categorized into G-CSF and non-G-CSF groups. Demographic and disease-related data were collected. Response rates, progression-free survival (PFS), overall survival (OS), and toxicity were analyzed.
UNASSIGNED: Of 119 patients (median age: 63 years), the overall response rate (ORR) and disease control rate (DCR) were 72.3% and 81.5%, respectively. In the G-CSF group, the ORR was 76.4% compared to 60.0% in the non-G-CSF group (p = 0.33), and the DCR was 85.4% versus 70.0%, respectively (p = 0.46). Median PFS was 8.3 months (95% CI, 6.8-9.8) in the G-CSF group and 6.8 months (95% CI, 6.2-7.5) in the non-G-CSF group (p = 0.24). Median OS was 13.8 months (95% CI, 9.6-18.1) for the G-CSF group and 10.6 months (95% CI, 7.9-13.3) for the non-G-CSF group (p = 0.47). Grade 3 ≥ adverse events were similar between groups (49.4% vs. 33.3%, respectively, p = 0.12).
UNASSIGNED: G-CSF prophylaxis can be safely used in ES-SCLC patients undergoing carboplatin plus etoposide and atezolizumab regimen without significantly altering efficacy or increasing toxicity.
UNASSIGNED: This retrospective, multicenter study enrolled ES-SCLC patients receiving carboplatin plus etoposide and atezolizumab, categorized into G-CSF and non-G-CSF groups. Demographic and disease-related data were collected. Response rates, progression-free survival (PFS), overall survival (OS), and toxicity were analyzed.
UNASSIGNED: Of 119 patients (median age: 63 years), the overall response rate (ORR) and disease control rate (DCR) were 72.3% and 81.5%, respectively. In the G-CSF group, the ORR was 76.4% compared to 60.0% in the non-G-CSF group (p = 0.33), and the DCR was 85.4% versus 70.0%, respectively (p = 0.46). Median PFS was 8.3 months (95% CI, 6.8-9.8) in the G-CSF group and 6.8 months (95% CI, 6.2-7.5) in the non-G-CSF group (p = 0.24). Median OS was 13.8 months (95% CI, 9.6-18.1) for the G-CSF group and 10.6 months (95% CI, 7.9-13.3) for the non-G-CSF group (p = 0.47). Grade 3 ≥ adverse events were similar between groups (49.4% vs. 33.3%, respectively, p = 0.12).
UNASSIGNED: G-CSF prophylaxis can be safely used in ES-SCLC patients undergoing carboplatin plus etoposide and atezolizumab regimen without significantly altering efficacy or increasing toxicity.
摘要：
■我们旨在评估粒细胞集落刺激因子（G-CSF）预防在广泛期小细胞肺癌（ES-SCLC）中使用卡铂联合依托泊苷和阿特珠单抗进行化学免疫治疗的有效性和安全性。
■这次回顾展，多中心研究纳入接受卡铂联合依托泊苷和阿替珠单抗治疗的ES-SCLC患者,分为G-CSF和非G-CSF组。收集人口统计学和疾病相关数据。响应率,无进展生存期（PFS），总生存期（OS），并对毒性进行了分析。
■119名患者（平均年龄：63岁），总有效率(ORR)和疾病控制率(DCR)分别为72.3%和81.5%,分别。在G-CSF组中,ORR为76.4%，而非G-CSF组为60.0%（p=0.33），DCR分别为85.4%和70.0%，分别(p=0.46)。G-CSF组为8.3个月（95%CI，6.8-9.8），非G-CSF组为6.8个月（95%CI，6.2-7.5）（p=0.24）。G-CSF组为13.8个月（95%CI，9.6-18.1），非G-CSF组为10.6个月（95%CI，7.9-13.3）（p=0.47）。3级≥不良事件组间相似(49.4%vs.33.3%,分别,p=0.12）。
■G-CSF预防可以安全地用于接受卡铂联合依托泊苷和阿特珠单抗方案的ES-SCLC患者，而不会显着改变疗效或增加毒性。
■这次回顾展，多中心研究纳入接受卡铂联合依托泊苷和阿替珠单抗治疗的ES-SCLC患者,分为G-CSF和非G-CSF组。收集人口统计学和疾病相关数据。响应率,无进展生存期（PFS），总生存期（OS），并对毒性进行了分析。
■119名患者（平均年龄：63岁），总有效率(ORR)和疾病控制率(DCR)分别为72.3%和81.5%,分别。在G-CSF组中,ORR为76.4%，而非G-CSF组为60.0%（p=0.33），DCR分别为85.4%和70.0%，分别(p=0.46)。G-CSF组为8.3个月（95%CI，6.8-9.8），非G-CSF组为6.8个月（95%CI，6.2-7.5）（p=0.24）。G-CSF组为13.8个月（95%CI，9.6-18.1），非G-CSF组为10.6个月（95%CI，7.9-13.3）（p=0.47）。3级≥不良事件组间相似(49.4%vs.33.3%,分别,p=0.12）。
■G-CSF预防可以安全地用于接受卡铂联合依托泊苷和阿特珠单抗方案的ES-SCLC患者，而不会显着改变疗效或增加毒性。
